In the ixekizumab every 2 weeks group , sPGA 0/1 was achieved by 292 ( response rate 832 % ; [ effect size 808 % ( 975 % CI 756-860 ) vs placebo ; 472 % ( 399-544 ) vs etanercept ] ) and 310 ( 805 % ; [ 738 % ( 677-799 ) vs placebo ; 389 % ( 317-461 ) vs etanercept ] ) patients ; in the ixekizumab every 4 weeks group by 253 ( 729 % ; [ 705 % ( 646-765 ) vs placebo ; 369 % ( 291-447 ) vs etanercept ] ) and 291 ( 754 % ; [ 687 % ( 623-750 ) vs placebo ; 338 % ( 263-413 ) vs etanercept ] ) patients ; in the placebo group by four ( 24 % ) and 13 ( 67 % ) patients ; and in the etanercept group by 129 ( 360 % ) and 159 ( 416 % ) patients ( all p < 00001 vs placebo or etanercept ) .